Stockreport

Did Higher 2026 Guidance and a New Shelf Offerings Plan Just Shift Arcutis' (ARQT) Investment Narrative? [Yahoo! Finance]

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF 2025 revenue reached US$376.07 million and net loss narrowed to US$16.14 million, alongside a filing for a universal shelf registration covering equity, debt, and relate [Read more]